Status:

COMPLETED

Galantamine Effects on Cognitive Function in Marijuana Users

Lead Sponsor:

Yale University

Collaborating Sponsors:

National Institute on Drug Abuse (NIDA)

US Department of Veterans Affairs

Conditions:

Memory

Eligibility:

All Genders

18-55 years

Phase:

PHASE1

Brief Summary

To evaluate galantamine's effects on cognitive performance in marijuana users. Galantamine, an acetylcholine esterase inhibitor, is approved for treatment of Alzheimer's disease. Current marijuana use...

Detailed Description

To summarize, marijuana users show impaired cognitive functioning, especially in working memory and verbal learning and memory functions. Impaired cognitive functioning predicts poor treatment respons...

Eligibility Criteria

Inclusion

  • Men and women between the ages of 18 and 55 who are dependent on or abuse marijuana, according to DSM-IV criteria;
  • History of marijuana use on the average of at least twice a week over a one-month period;
  • Current marijuana use, indicated by positive urine toxicology for marijuana;
  • No current medical problems and normal ECG;
  • For women, neither pregnant as determined by pregnancy screening nor breast feeding, and using acceptable birth control methods.

Exclusion

  • Current major psychiatric illnesses including mood, psychotic, or anxiety disorders;
  • Current dependence to other drugs of abuse or alcohol (except nicotine or marijuana dependence);
  • History of major medical illnesses including asthma or chronic obstructive lung disease, history or current gastrointestinal ulcer, hepatic or renal impairment and cardiac rhythm disturbances or other medical conditions that the study physician deems contraindicated for the subject to be in the study;
  • Use of other medications including a) drugs that slow heart rate (eg, beta-blockers),which may increase the risk of bradycardia and AV block and b) NSAIDs; increased potential for developing ulcers/active or occult gastrointestinal bleeding;
  • Known allergy to galantamine

Key Trial Info

Start Date :

August 1 2009

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

July 1 2011

Estimated Enrollment :

29 Patients enrolled

Trial Details

Trial ID

NCT00969696

Start Date

August 1 2009

End Date

July 1 2011

Last Update

July 25 2012

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Department of Veterans Affairs

West Haven, Connecticut, United States, 06516

Galantamine Effects on Cognitive Function in Marijuana Users | DecenTrialz